news, journals and articles from all over the world.
Researchers at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory are making progress on several fronts in the battle against COVID-19, the global pandemic sparked by the emergence of a novel coronavirus late last year. This work is part of a worldwide effort to understand the virus and the factors that affect its spread with the aim of devising treatments and other mitigation strategies.
With funding from the Coronavirus Aid, Relief and Economic Security (CARES) Act, Lawrence Livermore National Laboratory, chipmaker AMD and information technology company Supermicro have upgraded the supercomputing cluster Corona, providing additional resources to scientists for COVID-19 drug discovery and vaccine research
Researchers at Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have identified a cellular pathway that can be targeted with a naturally occurring drug to stimulate lung tissue regeneration, which is necessary for recovery from multiple lung injuries. The findings, which were published today in Nature Cell Biology, could lead to better therapies for patients with lung disease, including acute respiratory distress syndrome (ARDS) due to COVID-19.
High school summer students at Brookhaven Lab conduct computational studies, explore inhibitor drugs to disrupt COVID viral proteins that help infectious particles escape from cells.
When the COVID-19 pandemic hit, many students had to rejigger summer plans. Internships they’d expected to be in-person moved to all-virtual formats. For more than 30 students participating in virtual summer programs at the Brookhaven Lab, that disruption presented an opportunity—a chance to engage in research related to the virus responsible for the upheaval.
Structural biology techniques helped researchers target the nuclear receptor-binding SET domain family for the first time; its malfunction is associated with several types of cancer.
A new program in Biotechnology and Health Economics at Rensselaer Polytechnic Institute will equip students destined for a science-based career with the quantitative and modeling knowledge in economics needed to succeed in industry and consulting.
Laboratory research paves the way for a clinical trial to see if an FDA-approved drug used to prevent organ transplant rejection can work against glioblastoma, a type of aggressive brain tumor.
Researchers have discovered a new drug candidate that offers a major advance to treat diabetes. Tested on human and mouse pancreatic islets, mouse and rat cell cultures and animal models of Type 1 and Type 2 diabetes, the drug significantly improved four detrimental characteristics of diabetes.
In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease. The research is the latest example of a decoy strategy researchers at Rensselear Polytechnic Institute are developing against viruses like the novel coronavirus that spawned the current global health crisis.
A new cell profiling technology combines high throughput imaging and machine learning to provide a rapid, cost-effective way to determine how specific compounds act to destroy the bacterium that causes tuberculosis. It could speed discovery of anti-TB drugs and be applied to other pathogens.
Researchers have developed a new drug that prevents blood clots without causing an increased risk of bleeding, a common side effect of all antiplatelet medications currently available. A new study published in the journal Science Translational Medicine describes the drug and its delivery mechanisms and shows that the drug is also an effective treatment for heart attack in animal models.
The CDI will work with Merck to identify candidate treatments for the still-spreading pandemic.
At a glance:
• Scientists develop AI-based tool to predict adverse drug events
• Such events are responsible for some 2 million U.S. hospitalizations per year
• The free, open-source system could enable safer drug design, optimize drug safety
A team of scientists led by Abhishek Singharoy at Arizona State University used the Summit supercomputer at the Oak Ridge Leadership Computing Facility to simulate the structure of a possible drug target for the bacterium that causes rabbit fever.
University of Alabama in Huntsville (UAH) professor of biological science Dr. Jerome Baudry is collaborating with Hewlett Packard Enterprise (HPE) to use HPE’s Cray Sentinel supercomputer to search for natural products that are effective against the COVID-19 virus.
Fermilab, Brookhaven, and Open Science Grid dedicate computational power to COVID-19 research.
A new, free-to-use database of 14,000 known macrolactones fills a knowledge gap concerning these molecules and could serve as a useful tool for future drug discovery.
A team of scientists has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer.
The discovery marks a critical step toward developing a potential new class of anti-cancer drugs that enhance the activity of a prevalent family of tumor suppressor proteins.
A team of Stony Brook University (SBU) researchers is working on computer models that could help speed the discovery of drugs to combat the novel coronavirus responsible for COVID-19. They are doing this work in collaboration with scientists at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory and Argonne National Laboratory, and will be leveraging those laboratories’ computational resources and expertise.
Lawrence Livermore National Laboratory scientists are contributing to the global fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics and supercomputing to help discover candidates for new antibodies and pharmaceutical drugs to combat the disease.
To date, work done within the Tri-I TDI has resulted in the launch of two New York City–based companies and the licensing of six therapeutic discovery programs.
An anti-cancer compound developed at the University of Michigan has shown “profound” activity in mouse models against two subtypes of leukemia — representing up to 40% of patients — a U-M research team reports in the Journal of Clinical Investigation.
Lawrence Livermore National Laboratory engineers and biologists have developed a “brain-on-a-chip” device capable of recording the neural activity of living brain cell cultures in three-dimensions, a significant advancement in the realistic modeling of the human brain outside of the body.
Research by a University of Georgia psychologist shows that targeting one particular symptom of schizophrenia has a positive effect on other symptoms.
A collaboration between scientists at Rutgers University and The Scripps Research Institute led to the discovery of a small molecule that may slow down or stop the progression of Parkinson’s disease.
Scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore, and the Agency for Science, Technology and Research (A*STAR)’s Genome Institute of Singapore (GIS) have discovered four potential drug compounds that target hepatocellular carcinoma (HCC), the most common type of liver cancer.
Students from Long Island, New York, high schools have collaborated across districts to decipher the atomic-level structures of two proteins involved in a variety of diseases. The students used very bright x-rays at the National Synchrotron Light Source II at Brookhaven National Laboratory to identify the 3-D arrangements of atoms that make up functional components of these proteins.
A new technique reported in Science offers more detail, at the single cell level, on how large, pooled samples of various cells react to drugs or other agents. The data might reveal mode of action or the effect of genetic differences in varying responses.
Toxicological Sciences continues to deliver cutting-edge research in toxicology in the November 2019 issue. This issue features research on computational toxicology and databases, developmental and reproductive toxicology, and more.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have developed a machine-learning algorithm that gleans information from microscope images—allowing for high-throughput epigenetic drug screens that could unlock new treatments for cancer, heart disease, mental illness and more. The study was published in eLife.
Notre Dame’s $4.6 million award from the Department of Defense will help fund the expensive studies required before the compound can be given approval by the FDA to be tested on people.
The IU-led center is one of only two multi-institution teams in the nation selected as part of a new federal program intended to improve, diversify and reinvigorate the Alzheimer’s disease drug development pipeline.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu